Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

September 30, 1997

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Chronic Lymphocytic Leukemia
Interventions
BIOLOGICAL

Rituximab

Rituxan

DRUG

Fludarabine phosphate

Fludara

OTHER

Leukemic or stroma cells

Patients are eligible to donate cells for the purpose of analyzing leukemic cells. Cells can be donated by apheresis (e.g. 60-90 minute intravenous technique), lymph node biopsy (e.g. 3 biopsy/excision of lymph nodes)bone marrow biopsy (e.g. 2-4 separate bone marrow biopsies), and bone marrow aspiration (e.g. 3 to 5cc of marrow per aspirate).

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00001586 - Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis | Biotech Hunter | Biotech Hunter